FNCH
- · NASDAQ
- Sector -
- Industry -
- Website finchtherapeutics.com
- Employees(FY) 18
- ISIN -
Performance
-
1W
-32.78%
1M
-58.19%
3M
-65.82%
6M
-66.48%
YTD
-85.28%
1Y
Profile
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Technical Analysis of FNCH 2024-05-10
Overview:
In analyzing the technical indicators for FNCH over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming trading days.
Trend In...
Recent News & Updates
- 2021-08-09 19:00
- 2021-06-27 19:00
- 2021-05-27 19:00
- 2021-05-12 19:00
- 2021-05-05 19:00
- 2021-04-26 19:00
- 2021-03-19 04:25
- 2021-03-18 10:32
Page 3 of 3
previousnext